216 related articles for article (PubMed ID: 1615753)
1. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.
Warzocha K; Robak T
Acta Haematol Pol; 1992; 23(1):55-62. PubMed ID: 1615753
[TBL] [Abstract][Full Text] [Related]
2. The influence of recombinant human tumor necrosis factor-alpha, alone and in combination with cyclophosphamide or methotrexate, on leukemia L1210 and normal hematopoiesis in mice.
Warzocha K; Robak T; Korycka A; Graczyk J; Pakulska W; Gałazka G; Kłysik J
Arch Immunol Ther Exp (Warsz); 1991; 39(5-6):587-95. PubMed ID: 1841555
[TBL] [Abstract][Full Text] [Related]
3. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
Góra-Tybor J; Robak T
Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
[TBL] [Abstract][Full Text] [Related]
5. Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210.
Góra-Tybor J; Robak T; Warzocha K; Grieb P
Arch Immunol Ther Exp (Warsz); 1994; 42(1):39-42. PubMed ID: 7503633
[TBL] [Abstract][Full Text] [Related]
6. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide plus methotrexate in murine L1210 leukemia.
Klubes P; Cerna I
Cancer Treat Rep; 1981; 65(1-2):107-14. PubMed ID: 7226161
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
10. Chemoimmunotherapy of B 16 melanoma and P388 leukemia with cyclophosphamide and pyrimidinones.
Li LH; Johnson MA; Moeller RB; Wallace TL
Cancer Res; 1984 Jul; 44(7):2841-7. PubMed ID: 6722813
[TBL] [Abstract][Full Text] [Related]
11. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
[TBL] [Abstract][Full Text] [Related]
12. 6-Mercaptopurine-induced potentiation of active immunotherapy in L1210-bearing mice treated with concanavalin A-bound leukemia cell vaccine.
Kataoka T; Akahori Y; Sakurai Y
Cancer Res; 1984 Feb; 44(2):519-24. PubMed ID: 6537896
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388.
Robak T; Szmigielska A
Neoplasma; 2000; 47(3):168-71. PubMed ID: 11043840
[TBL] [Abstract][Full Text] [Related]
14. Interactions of 2',2'-diflurodeoxycytidine (gemcitabine) with tumor necrosis factor alpha or its mutein VI in murine leukemias L1210 and P388.
Marańda E; Robak T
Arch Immunol Ther Exp (Warsz); 1998; 46(2):113-9. PubMed ID: 9613709
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions.
Inagawa H; Nishizawa T; Honda T; Nakamoto T; Takagi K; Soma G
Anticancer Res; 1998; 18(5D):3957-64. PubMed ID: 9854510
[TBL] [Abstract][Full Text] [Related]
16. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
Avery TL; Roberts D
Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
[TBL] [Abstract][Full Text] [Related]
17. Predictive values of the in vivo diffusion chamber for cyclophosphamide treatment of L1210 murine leukemia.
Anderson KC; Humphrey RL; Sensenbrenner LL
Cancer Res; 1983 May; 43(5):2030-3. PubMed ID: 6831434
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice.
Feleszko W; Lasek W; Gołab J; Jakóbisiak M
Neoplasma; 1995; 42(2):69-74. PubMed ID: 7617079
[TBL] [Abstract][Full Text] [Related]
19. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor.
Creasey AA; Reynolds MT; Laird W
Cancer Res; 1986 Nov; 46(11):5687-90. PubMed ID: 3756916
[TBL] [Abstract][Full Text] [Related]
20. Chemoimmunotherapy of L1210 leukemia with adriamycin, cyclophosphamide, and OK-432, and their effects on the generation of antitumor immunity.
Ujiie T
Jpn J Cancer Res; 1987 Jul; 78(7):737-47. PubMed ID: 3114200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]